{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:39:39Z","timestamp":1792823979587,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.canlet.2026.218850","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:14:06Z","timestamp":1789830846000},"page":"218850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CD20 targeted nanomedicine enhances anti-tumor immunity in diffuse large B-cell lymphoma by activating cGAS\/STING pathway"],"prefix":"10.1016","volume":"661","author":[{"given":"Zuofei","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cen","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruowen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218850_bib1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.canlet.2026.218850_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and etiology of diffuse large B-cell lymphoma","volume":"60","author":"Wang","year":"2023","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.canlet.2026.218850_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3202","article-title":"Diffuse large B-cell lymphoma","volume":"42","author":"Barraclough","year":"2024","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218850_bib4","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/cncr.35158","article-title":"Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray","volume":"130","author":"Dai","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2026.218850_bib5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/bjh.19295","article-title":"New standards of care for treatment of diffuse large B-cell lymphoma","volume":"204","author":"Abeyakoon","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2026.218850_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review","volume":"14","author":"Camicia","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218850_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102443","article-title":"Treatment strategies for patients with diffuse large B-cell lymphoma","volume":"110","author":"Poletto","year":"2022","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2026.218850_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3324\/haematol.2018.211490","article-title":"A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models","volume":"105","author":"Falg\u00e0s","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2026.218850_bib9","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2147\/IJN.S289733","article-title":"Specific cytotoxic effect of an Auristatin nanoconjugate towards CXCR4(+) diffuse large B-Cell lymphoma cells","volume":"16","author":"Falg\u00e0s","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2026.218850_bib10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218850_bib11","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \"enigma\" of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2026.218850_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107552","article-title":"An overview on anti-tubulin agents for the treatment of lymphoma patients","volume":"211","author":"Barreca","year":"2020","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.canlet.2026.218850_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.bbcan.2018.12.007","article-title":"Targeting mitosis exit: a brake for cancer cell proliferation","volume":"1871","author":"Liu","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2026.218850_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10555-025-10271-5","article-title":"Role of PLK4 inhibition in cancer therapy","volume":"44","author":"Banik","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2026.218850_bib15","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41419-021-03919-x","article-title":"Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma","volume":"12","author":"Zhao","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218850_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/cm.22031","article-title":"PLK4: master regulator of Centriole duplication and its therapeutic potential","author":"Hamzah","year":"2025","journal-title":"Cytoskeleton (Hoboken, N.J.)"},{"key":"10.1016\/j.canlet.2026.218850_bib17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/bjh.18872","article-title":"Resistance to vincristine in DLBCL by disruption of p53-induced cell cycle arrest and apoptosis mediated by KIF18B and USP28","volume":"202","author":"Rovsing","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2026.218850_bib18","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-11-2413","article-title":"Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell Non-Hodgkin lymphoma","volume":"18","author":"Mahadevan","year":"2012","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2026.218850_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095184","article-title":"Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2","volume":"9","author":"Mahadevan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218850_bib20","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1158\/1078-0432.CCR-18-0286","article-title":"Phase I Study of the investigational Aurora A kinase inhibitor Alisertib plus Rituximab or Rituximab\/Vincristine in Relapsed\/Refractory aggressive B-cell lymphoma","volume":"24","author":"Kelly","year":"2018","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2026.218850_bib21","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1038\/s41467-023-38784-z","article-title":"TRABID inhibition activates cGAS\/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation","volume":"14","author":"Chen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218850_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41389-024-00518-1","article-title":"Mitotic MTH1 inhibitor TH1579 induces PD-L1 expression and inflammatory response through the cGAS-STING pathway","volume":"13","author":"Shen","year":"2024","journal-title":"Oncogenesis"},{"key":"10.1016\/j.canlet.2026.218850_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216695","article-title":"Inhibiting autophagy enhanced mitotic catastrophe-mediated anticancer immune responses by regulating the cGAS-STING pathway","volume":"586","author":"Bai","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218850_bib24","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2023019782","article-title":"Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML","volume":"142","author":"Man","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218850_bib25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jconrel.2023.11.049","article-title":"Zeolite imidazolate framework-8 in bone regeneration: a systematic review","volume":"365","author":"Tang","year":"2024","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"key":"10.1016\/j.canlet.2026.218850_bib26","doi-asserted-by":"crossref","first-page":"20861","DOI":"10.1021\/acs.inorgchem.3c02322","article-title":"Structural chemistry of zeolitic imidazolate frameworks","volume":"62","author":"Zheng","year":"2023","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.canlet.2026.218850_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2024.103153","article-title":"Zeolitic imidazolate frameworks (ZIFs): advanced nanostructured materials to enhance the functional performance of food packaging materials","volume":"327","author":"Alizadeh Sani","year":"2024","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.canlet.2026.218850_bib28","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ad713f","article-title":"Enhanced anti-tumor and anti-metastatic activity of quercetin using pH-sensitive Alginate@ZIF-8 nanocomposites:in vitroandin vivostudy","volume":"35","author":"Rostamkhani","year":"2024","journal-title":"Nanotechnology"},{"key":"10.1016\/j.canlet.2026.218850_bib29","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1039\/D3BM00306J","article-title":"Macro-microporous ZIF-8 MOF complexed with lysosomal pH-adjusting hexadecylsulfonylfluoride as tumor vaccine delivery systems for improving anti-tumor cellular immunity","volume":"11","author":"Zuo","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.canlet.2026.218850_bib30","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.2147\/IJN.S449820","article-title":"Synergistic photothermal tumor immunotherapy by 1-MT based on zeolitic imidazolate Framework-8 with pH-High sensitivity","volume":"19","author":"Su","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2026.218850_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","article-title":"Targeting STING to promote antitumor immunity","volume":"33","author":"Chin","year":"2023","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2026.218850_bib32","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","article-title":"Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy","volume":"30","author":"Lv","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2026.218850_bib33","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood.2023020779","article-title":"DLBCL: who is high risk and how should treatment be optimized?","volume":"144","author":"Dabrowska-Iwanicka","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218850_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.biomaterials.2019.01.001","article-title":"Dual ATP and pH responsive ZIF-90 nanosystem with favorable biocompatibility and facile post-modification improves therapeutic outcomes of triple negative breast cancer in vivo","volume":"197","author":"Jiang","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218850_bib35","first-page":"11139","article-title":"Water-based synthesis of zeolitic imidazolate framework-90 (ZIF-90) with a controllable particle size","volume":"19","author":"Shieh","year":"2013","journal-title":"Chemistry (Weinheim an der Bergstrasse, Germany)"},{"key":"10.1016\/j.canlet.2026.218850_bib36","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1039\/c3ta10928c","article-title":"Room-temperature synthesis of ZIF-90 nanocrystals and the derived nano-composite membranes for hydrogen separation","volume":"1","author":"Yang","year":"2013","journal-title":"J. Mater. Chem. A"},{"key":"10.1016\/j.canlet.2026.218850_bib37","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1021\/acsami.5b11760","article-title":"Versatile synthesis and fluorescent labeling of ZIF-90 nanoparticles for biomedical applications","volume":"8","author":"Jones","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218850_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/nano14110975","article-title":"Long-Term stable cycling of dendrite-free lithium metal batteries using ZIF-90@PP composite separator","volume":"14","author":"Lyu","year":"2024","journal-title":"Nanomaterials"},{"key":"10.1016\/j.canlet.2026.218850_bib39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcis.2023.04.126","article-title":"Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin","volume":"646","author":"Cai","year":"2023","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.canlet.2026.218850_bib40","doi-asserted-by":"crossref","first-page":"53460","DOI":"10.1021\/acsami.4c10562","article-title":"Functional ginger-derived extracellular vesicles-coated ZIF-8 containing TNF-\u03b1 siRNA for ulcerative colitis therapy by modulating Gut Microbiota","volume":"16","author":"Cui","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218850_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.129233","article-title":"Tumor-targeted delivery of SNHG15 siRNA using a ZIF-8 nanoplatform: towards a more effective prostate cancer therapy","volume":"259","author":"Saeinasab","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.canlet.2026.218850_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.125380","article-title":"Preparation and biological evaluation of antibody targeted metal-organic framework drug delivery system (TDDS) in Her2 receptor-positive cells","volume":"269","author":"Chen","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.canlet.2026.218850_bib43","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S36111","article-title":"The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles","volume":"7","author":"Fr\u00f6hlich","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.canlet.2026.218850_bib44","article-title":"Biotin decorated celastrol-loaded ZIF-8 nano-drug delivery system targeted epithelial ovarian cancer therapy","volume":"167","author":"Zhou","year":"2023","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218850_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102179","article-title":"Res@ZIF-90 suppress gastric cancer progression by disturbing mitochondrial homeostasis","volume":"51","author":"Qiu","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2026.218850_bib46","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.canlet.2026.218850_bib47","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1016\/S2352-3026(21)00212-X","article-title":"Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India","volume":"8","author":"Nair","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.canlet.2026.218850_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13046-017-0492-6","article-title":"Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells","volume":"36","author":"Zhou","year":"2017","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"key":"10.1016\/j.canlet.2026.218850_bib49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.biomaterials.2018.10.007","article-title":"Biorecognition: a key to drug-free macromolecular therapeutics","volume":"190\u2013191","author":"Yang","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218850_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27217202","article-title":"Fabrication of pH-Responsive Zn(2+)-Releasing glass particles for smart antibacterial restoratives","volume":"27","author":"Deng","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.canlet.2026.218850_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202300303","article-title":"Zinc-Based tannin-modified composite microparticulate scaffolds with balanced antimicrobial activity and osteogenesis for infected bone defect repair","volume":"12","author":"Zhao","year":"2023","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.canlet.2026.218850_bib52","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1038\/s41596-023-00868-x","article-title":"Enzyme immobilization on covalent organic framework supports","volume":"18","author":"Zhu","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2026.218850_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16030414","article-title":"Synthesis and characterization of ZIF-90 nanoparticles as potential brain cancer therapy","volume":"16","author":"Monarca","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.canlet.2026.218850_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2024.141188","article-title":"Functional groups effect on the toxicity of modified ZIF-90 to Photobacterium phosphoreum","volume":"351","author":"Wang","year":"2024","journal-title":"Chemosphere"},{"key":"10.1016\/j.canlet.2026.218850_bib55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1146\/annurev-immunol-101721-032910","article-title":"Regulation of the cGAS-STING pathway","volume":"43","author":"Zhang","year":"2025","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218850_bib56","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41586-019-1000-2","article-title":"Structural basis of STING binding with and phosphorylation by TBK1","volume":"567","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218850_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216700","article-title":"STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs)","volume":"588","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218850_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217544","article-title":"Traditional medicine Bazi Bushen potentiates immunosurveillance of senescent liver cancer cells via cGAS-STING signaling activation in macrophages","volume":"627","author":"Xing","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218850_bib59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41577-024-01112-7","article-title":"Regulation of cGAS-STING signalling and its diversity of cellular outcomes","volume":"25","author":"Zhang","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218850_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216409","article-title":"cGAS-STING signaling in the tumor microenvironment","volume":"577","author":"Liu","year":"2023","journal-title":"Cancer Lett."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:23:36Z","timestamp":1792823016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":60,"alternative-id":["S0304383526006142"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218850","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD20 targeted nanomedicine enhances anti-tumor immunity in diffuse large B-cell lymphoma by activating cGAS\/STING pathway","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218850"}}